Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review

Pharvaris reported that Phase 3 data from the RAPIDe-3 trial indicates that deucrictibant IR provides symptom relief for HAE attacks in an average of 1.28 hours and complete resolution in 11.95 hours. The treatment demonstrated a well-tolerated safety profile. The New Drug Application (NDA) and Marketing Authorization Application (MAA) for deucrictibant IR are currently under review by regulatory authorities.